Circulation Research, Vol 73, 51-60, Copyright © 1993 by American Heart Association

ARTICLES

Measurement of angiotensin I converting enzyme inhibition in the heart

A Kinoshita, H Urata, FM Bumpus and A Husain
Department of Cardiovascular Biology, Research Institute, OH 44195-5071.

Angiotensin (Ang) I converting enzyme (ACE) inhibitors represent a major advance in the treatment of congestive heart failure, and tissue, rather than circulating ACE, may be their major site of action. However, assessments of tissue ACE inhibition in treated patients has not always supported this contention. In these studies, ACE activity was measured in homogenates of sampled tissue by biochemical methods. In the present study, using a model system, we have examined the validity of these tissue-sampling methods. Functional ACE activity was determined by comparing positive inotropic responses to [Pro10]Ang I in either vehicle-pretreated or ACE inhibitor-pretreated papillary muscles. [Pro10]Ang I elicits a response, which is entirely dependent on ACE-mediated conversion to Ang II. The ACE inhibitors studied were captopril, enalaprilat, lisinopril, and quinaprilat. In a parallel study, papillary muscle ACE activity was also measured in homogenates using [125I]MK-351A (a radiolabeled ACE inhibitor) binding. The studies indicate that the tissue-sampling method significantly underestimated functional ACE inhibition in hamster papillary muscles (p < 0.001). Kinetic studies indicated that the half-time for the dissociation of [3H]enalaprilat and [3H]lisinopril from hamster ventricular ACE was 4.5 and 6.2 minutes, respectively. The dissociation of [3H]quinaprilat was biphasic (half-time, 47 and 90 minutes), indicating that the two active sites of somatic ACE differ in their ability to bind to this inhibitor. The rapid rate of ACE inhibitor dissociation suggests that, during the time taken to assay ACE activity biochemically, the enzyme becomes "disinhibited," leading to an underestimation of functional ACE inhibition. ACE inhibitor dissociation rates were partially predictive of the duration of functional ACE inhibition in papillary muscles; other factors that appeared to contribute were "tissue trapping" of the inhibitor and de novo synthesis of ACE in papillary muscles. Quantification of tissue ACE inhibition and its relation to drug efficacy must, therefore, involve a careful consideration of these factors to avoid artifacts in clinical decision making and in assessments of pathogenic mechanisms involved in congestive heart failure.

This article has been cited by other articles:

				M. E. Moreau, P. Dubreuil, G. Molinaro, M. Chagnon, W. Muller-Esterl, Y. Lepage, F. Marceau, and A. Adam Expression of Metallopeptidases and Kinin Receptors in Swine Oropharyngeal Tissues: Effects of Angiotensin I-Converting Enzyme Inhibition and Inflammation J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1065 - 1074. [Abstract] [Full Text] [PDF]

				C. J. Pepine, J.-L. Rouleau, K. Annis, A. Ducharme, P. Ma, J. Lenis, R. Davies, U. Thadani, B. Chaitman, H. E. Haber, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: The quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2049 - 2059. [Abstract] [Full Text] [PDF]

				J. R. Freshour, S. E. Chase, and K. L. Vikstrom Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1997 - H2003. [Abstract] [Full Text] [PDF]

				V. Richard, S. Hurel-Merle, E. Scalbert, G. Ferry, F. Lallemand, J.-P. Bessou, and C. Thuillez Functional Evidence for a Role of Vascular Chymase in the Production of Angiotensin II in Isolated Human Arteries Circulation, August 14, 2001; 104(7): 750 - 752. [Abstract] [Full Text] [PDF]

				C. Blais Jr., D. Fortin, J.-L. Rouleau, G. Molinaro, and A. Adam Protective Effect of Omapatrilat, a Vasopeptidase Inhibitor, on the Metabolism of Bradykinin in Normal and Failing Human Hearts J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 621 - 626. [Abstract] [Full Text]

				A. J. M. Roks, P. P. van Geel, Y. M. Pinto, H. Buikema, R. H. Henning, D. de Zeeuw, and W. H. van Gilst Angiotensin-(1–7) Is a Modulator of the Human Renin-Angiotensin System Hypertension, August 1, 1999; 34(2): 296 - 301. [Abstract] [Full Text] [PDF]

				R. Raut, J.-L. Rouleau, C. Blais Jr., H. Gosselin, G. Molinaro, M. G. Sirois, Y. Lepage, P. Crine, and A. Adam Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11 Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1769 - H1779. [Abstract] [Full Text] [PDF]

				J.-L. Liu and I. H. Zucker Regulation of Sympathetic Nerve Activity in Heart Failure : A Role for Nitric Oxide and Angiotensin II Circ. Res., March 5, 1999; 84(4): 417 - 423. [Abstract] [Full Text] [PDF]

				B. Hornig, N. Arakawa, D. Haussmann, and H. Drexler Differential Effects of Quinaprilat and Enalaprilat on Endothelial Function of Conduit Arteries in Patients With Chronic Heart Failure Circulation, December 22, 1998; 98(25): 2842 - 2848. [Abstract] [Full Text]

				H. Nishimura, H. Buikema, O. Baltatu, D. Ganten, and H. Urata Functional evidence for alternative ANG II-forming pathways in hamster cardiovascular system Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1307 - H1312. [Abstract] [Full Text] [PDF]

				C. Blais Jr., G. Drapeau, P. Raymond, D. Lamontagne, N. Gervais, I. Venneman, and A. Adam Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study Am J Physiol Heart Circ Physiol, November 1, 1997; 273(5): H2263 - H2271. [Abstract] [Full Text] [PDF]

				F. G. Spinale, M. de Gasparo, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, R. S. Krombach, R. Mukherjee, J. P. Iannini, and S.-J. O Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : I. Effects on Left Ventricular Performance and Neurohormonal Systems Circulation, October 7, 1997; 96(7): 2385 - 2396. [Abstract] [Full Text]

				E. Balcells, Q. C. Meng, W. H. Johnson Jr., S. Oparil, and L. J. Dell'Italia Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H1769 - H1774. [Abstract] [Full Text] [PDF]

				K. C. Wollert, R. Studer, K. Doerfer, E. Schieffer, C. Holubarsch, H. Just, and H. Drexler Differential Effects of Kinins on Cardiomyocyte Hypertrophy and Interstitial Collagen Matrix in the Surviving Myocardium After Myocardial Infarction in the Rat Circulation, April 1, 1997; 95(7): 1910 - 1917. [Abstract] [Full Text]

				A. Wolny, J.-P. Clozel, J. Rein, P. Mory, P. Vogt, M. Turino, W. Kiowski, and W. Fischli Functional and Biochemical Analysis of Angiotensin II–Forming Pathways in the Human Heart Circ. Res., February 1, 1997; 80(2): 219 - 227. [Abstract] [Full Text]

				M. Ruzicka, V. Skarda, and F. H.H. Leenen Effects of ACE Inhibitors on Circulating Versus Cardiac Angiotensin II in Volume OverloadInduced Cardiac Hypertrophy in Rats Circulation, December 15, 1995; 92(12): 3568 - 3573. [Abstract] [Full Text]

				P. H. Rolland, A. Friggi, A. Barlatier, P. Piquet, V. Latrille, M. M. Faye, J. Guillou, P. Charpiot, H. Bodard, O. Ghiringhelli, et al. Hyperhomocysteinemia-Induced Vascular Damage in the Minipig : Captopril-Hydrochlorothiazide Combination Prevents Elastic Alterations Circulation, February 15, 1995; 91(4): 1161 - 1174. [Abstract] [Full Text]

				G. Bruckschlegel, S. R. Holmer, K. Jandeleit, D. Grimm, F. Muders, E. P. Kromer, G. A. J. Riegger, and H. Schunkert Blockade of the Renin-Angiotensin System in Cardiac Pressure-Overload Hypertrophy in Rats Hypertension, February 1, 1995; 25(2): 250 - 259. [Abstract] [Full Text]